Respiratory News and Research

RSS

Bonis project develops multimedia system to identify dengue plague and febrile illnesses in Paraguay

Xabier Basogain Olabe (Donostia-San Sebasti-n, 1962), lecturer at the Higher Technical School of Engineering in Bilbao, is leading this project, known as Bonis. It involves developing a multimedia system in order to undertake visual monitoring of epidemiology in isolated areas of Paraguay and thus avoid the dengue plague and other febrile illnesses.

29 Mar 2010

TB-causing bacteria can hijack fat metabolism to drive progression of the disease

The factors instrumental in triggering latent tuberculosis infection to progress into active disease have long remained elusive to researchers. New insight into the mystery is provided by Professor David Russell, speaking at the Society for General Microbiology's spring meeting in Edinburgh today. His work could help develop innovative strategies for treating the disease.

29 Mar 2010

APHA petitioned EPA to adopt protective standards to safeguard public health from ground-level ozone

The American Public Health Association this week petitioned the U.S. Environmental Protection Agency to adopt stronger, more protective standards to safeguard the health of the public from ground-level ozone.

27 Mar 2010

Agent Orange exposure: VA adds three new illnesses to list of health problems

Well over 100,000 Veterans exposed to herbicides while serving in Vietnam and other areas will have an easier path to qualify for disability pay under a proposed regulation published by the Department of Veterans Affairs (VA) that adds three new illnesses to the list of health problems found to be related to Agent Orange and other herbicide exposures.

27 Mar 2010

Two EMBEDA video news releases misleading, warns FDA DDMAC

On October 8, 2009, King Pharmaceuticals, Inc. received a Warning Letter from the Division of Drug Marketing, Advertising, and Communications (DDMAC) at the Food and Drug Administration regarding two video news releases - EMBEDA Media backgrounder, and EMBEDA Visual Media Technology, for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use C-II.

27 Mar 2010

BLS acquires AMPAKINE compounds from Cortex Pharmaceuticals

Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL, has acquired certain AMPAKINE® compounds, including associated intellectual property, from Cortex Pharmaceuticals, Inc. for use in the field of respiratory depression, a brain-mediated breathing disorder.

26 Mar 2010

Global home health management market expanding at CAGR of 10% through 2012

Remote health management is the fastest growing segment of a burgeoning home health management market. However, RHM’s full potential will materialize only if health insurers adopt reimbursement practices that encourage greater physician adoption, concludes Scientia Advisors, a global strategy consulting firm, in its review of the worldwide home health management market released today.

26 Mar 2010

Ingen Technologies set to expand into government and export markets

Ingen Technologies, Inc., the leading manufacturer of in-line oxygen flow meters for respiratory medical devices, which helps companies similar to McKesson Corporation and Amedisys Inc. achieve substantial cost-savings by reducing support costs for in-home oxygen patients, recently announced that the company is set to expand into government and export markets.

26 Mar 2010

New report urges government to ban smoking in cars to limit children's exposure to passive smoke

A new report released by the Tobacco Advisory Group of the Royal College of Physicians urges the government to ban smoking in cars and other public vehicles to limit children's exposure to passive smoke.

26 Mar 2010

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

26 Mar 2010

Pay-For-Performance program to improve quality of patient care

The ATS has released an official policy statement of pay-for-performance (P4P) in pulmonary, critical care and sleep medicine. In the statement, the Society encourages clinicians in these fields to participate in P4P programs and views them as an opportunity to partner with healthcare payors, accrediting organizations, governmental oversight groups and others to improve quality, rather than as a threat to autonomy and independence.

25 Mar 2010

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fourth quarter and full year ended December 31, 2009.

25 Mar 2010

New study investigates effects of influenza among pregnant women

This spring, pregnant women in Bergen and Oslo will be invited to take part in the Norwegian Influenza Study (NorFlu). The aim is to find out how influenza in pregnancy affects maternal health and childhood development. NorFlu will also study any implications of vaccination during pregnancy.

25 Mar 2010

Expert testimony in trial of Dr Patel

Dr Jayant Patel’s manslaughter trial in the supreme court of Brisbane saw Dr Nigel Chikolwa give testimony about the deteriorating condition of Mr Morris after surgery. Dr Chikolwa was the principal house officer at Bundaberg hospital, where Dr Patel had performed the surgery in 2003.

25 Mar 2010

TB prevalence more common among HIV patients and aged individuals

A study by the Barcelona Public Health Agency has revealed those sections of the population that are most vulnerable to tuberculosis. The research, published in the journal Respiratory Research, shows that the highest death rates from this disease are among those aged over 50 or infected with HIV.

24 Mar 2010

GSK joins GAVI Alliance in the Pneumococcal disease vaccine drive

GSK has become one of the first manufacturers to sign a unique agreement with the GAVI Alliance that has the potential to save millions of children from dying in the world's poorest countries. GSK will supply up to 300 million doses of its vaccine Synflorix, for invasive pneumococcal disease, to GAVI over a ten year period. Pneumococcal disease is a leading cause of death in children under the age of five in developing countries.

24 Mar 2010

Aradigm reports net loss of $3.4M for fourth-quarter 2009

Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2009.

23 Mar 2010

FDA approves APP Pharmaceuticals' Indomethacin for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Indomethacin for Injection. Indomethacin is therapeutically equivalent to the reference-listed drug INDOCIN® I.V., by Lundbeck, Inc.

23 Mar 2010

Ingen Technologies achieves ISO 13485 Certification

Ingen Technologies, Inc., a leading manufacturer of respiratory medical devices, recently announced today that the company is officially ISO 13485 Certified.

22 Mar 2010

FDA convenes Advisory Committee meeting to discuss safety of LABA's

On Wednesday, March 10 and Thursday, March 11, the FDA is convening an Advisory Committee meeting on the clinical trial design for long acting beta-2 adrenergic agonists.

22 Mar 2010